Pharmacotherapy for managing extraglandular symptoms of primary Sjögren’s syndrome

Bibliography

• Fox RI. Sjogren’s syndrome. Lancet 2005;366:321-31
   PubMed Web of Science ®Google Scholar
• Qin B, Wang J, Yang Z, et al. Epidemiology of primary Sjogren’s syndrome: a systematic review and meta-analysis. Ann Rheum Dis 2014. [Epub ahead of print]
   Web of Science ®Google Scholar
• Kvarnstrom M, Ottosson V, Nordmark B, et al. Incident cases of primary Sjogren’s syndrome during a 5-year period in stockholm county: a descriptive study of the patients and their characteristics. Scand J Rheumatol 2014;15:1-8
   Google Scholar
• Voulgarelis M, Tzioufas AG. Pathogenetic mechanisms in the initiation and perpetuation of Sjogren’s syndrome. Nat Rev Rheumatol 2010;6:529-37
   PubMed Web of Science ®Google Scholar
• Pijpe J, Kalk WW, van der Wal JE, et al. Parotid gland biopsy compared with labial biopsy in the diagnosis of patients with primary Sjogren’s syndrome. Rheumatology (Oxford) 2007;46:335-41
   PubMed Web of Science ®Google Scholar
• Risselada AP, Looije MF, Kruize AA, et al. The role of ectopic germinal centers in the immunopathology of primary Sjogren’s syndrome: a systematic review. Semin Arthritis Rheum 2013;42:368-76
   PubMed Web of Science ®Google Scholar
• Salomonsson S, Jonsson MV, Skarstein K, et al. Cellular basis of ectopic germinal center formation and autoantibody production in the target organ of patients with Sjogren’s syndrome. Arthritis Rheum 2003;48:3187-201
   PubMed Web of Science ®Google Scholar
• Manoussakis MN, Kapsogeorgou EK. The role of intrinsic epithelial activation in the pathogenesis of Sjogren’s syndrome. J Autoimmun 2010;35:219-24
   PubMed Web of Science ®Google Scholar
• Salomonsson S, Rozell BL, Heimburger M, et al. Minor salivary gland immunohistology in the diagnosis of primary Sjogren’s syndrome. J Oral Pathol Med 2009;38:282-8
   PubMed Web of Science ®Google Scholar
• Kroese FG, Abdulahad WH, Haacke E, et al. B-cell hyperactivity in primary Sjogren’s syndrome. Expert Rev Clin Immunol 2014;10:483-99
   PubMed Web of Science ®Google Scholar
• Ittah M, Miceli-Richard C, Gottenberg JE, et al. B cell-activating factor of the tumor necrosis factor family (BAFF) is expressed under stimulation by interferon in salivary gland epithelial cells in primary Sjogren’s syndrome. Arthritis Res Ther 2006;8:R51
   PubMed Web of Science ®Google Scholar
• Brkic Z, Maria NI, van Helden-Meeuwsen CG, et al. Prevalence of interferon type I signature in CD14 monocytes of patients with Sjogren’s syndrome and association with disease activity and BAFF gene expression. Ann Rheum Dis 2013;72:728-35
   PubMed Web of Science ®Google Scholar
• Gottenberg JE, Cagnard N, Lucchesi C, et al. Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjogren’s syndrome. Proc Natl Acad Sci USA 2006;103:2770-5
   PubMed Web of Science ®Google Scholar
• Pollard RP, Abdulahad WH, Vissink A, et al. Serum levels of BAFF, but not APRIL, are increased after rituximab treatment in patients with primary Sjogren’s syndrome: data from a placebo-controlled clinical trial. Ann Rheum Dis 2013;72:146-8
   PubMed Web of Science ®Google Scholar
• Lessard CJ, Li H, Adrianto I, et al. Variants at multiple loci implicated in both innate and adaptive immune responses are associated with Sjogren’s syndrome. Nat Genet 2013;45:1284-92
   PubMed Web of Science ®Google Scholar
• Pollard RP, Abdulahad WH, Bootsma H, et al. Predominantly proinflammatory cytokines decrease after B cell depletion therapy in patients with primary Sjogren’s syndrome. Ann Rheum Dis 2013;72:2048-50
   PubMed Web of Science ®Google Scholar
• Tanaka T, Narazaki M, Ogata A, et al. A new era for the treatment of inflammatory autoimmune diseases by interleukin-6 blockade strategy. Semin Immunol 2014;26:88-96
   PubMed Web of Science ®Google Scholar
• Diehl SA, Schmidlin H, Nagasawa M, et al. IL-6 triggers IL-21 production by human CD4+ T cells to drive STAT3-dependent plasma cell differentiation in B cells. Immunol Cell Biol 2012;90:802-11
   PubMed Web of Science ®Google Scholar
• Bryant VL, Ma CS, Avery DT, et al. Cytokine-mediated regulation of human B cell differentiation into Ig-secreting cells: predominant role of IL-21 produced by CXCR5+ T follicular helper cells. J Immunol 2007;179:8180-90
   PubMed Web of Science ®Google Scholar
• Shulman Z, Gitlin AD, Weinstein JS, et al. Dynamic signaling by T follicular helper cells during germinal center B cell selection. Science 2014;345:1058-62
   PubMed Web of Science ®Google Scholar
• Lund FE, Randall TD. Effector and regulatory B cells: modulators of CD4(+) T cell immunity. Nat Rev Immunol 2010;10:236-47
   PubMed Web of Science ®Google Scholar
• Bettelli E, Carrier Y, Gao W, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006;441:235-8
   PubMed Web of Science ®Google Scholar
• Ciccia F, Guggino G, Rizzo A, et al. Rituximab modulates IL-17 expression in the salivary glands of patients with primary Sjogren’s syndrome. Rheumatology (Oxford) 2014;53:1313-20
   PubMed Web of Science ®Google Scholar
• Katsifis GE, Rekka S, Moutsopoulos NM, et al. Systemic and Local Interleukin-17 and Linked Cytokines Associated with Sjögren’s Syndrome Immunopathogenesis. Am J Pathol 2009;175:1167-77
   PubMed Web of Science ®Google Scholar
• Nguyen CQ, Hu MH, Li Y, et al. Salivary gland tissue expression of interleukin-23 and interleukin-17 in Sjogren’s syndrome: findings in humans and mice. Arthritis Rheum 2008;58:734-43
   PubMed Web of Science ®Google Scholar
• Jacobs JP, Wu HJ, Benoist C, et al. IL-17-producing T cells can augment autoantibody-induced arthritis. Proc Natl Acad Sci USA 2009;106:21789-94
   PubMed Web of Science ®Google Scholar
• Fleige H, Ravens S, Moschovakis GL, et al. IL-17-induced CXCL12 recruits B cells and induces follicle formation in BALT in the absence of differentiated FDCs. J Exp Med 2014;211:643-51
   PubMed Web of Science ®Google Scholar
• Lin X, Rui K, Deng J, et al. Th17 cells play a critical role in the development of experimental Sjogren’s syndrome. Ann Rheum Dis 2014;73(7):e43
   PubMedGoogle Scholar
• Alunno A, Carubbi F, Bartoloni E, et al. Unmasking the pathogenic role of IL-17 axis in primary Sjogren’s syndrome: a new era for therapeutic targeting? Autoimmun Rev 2014;13(12):1167-73
   PubMed Web of Science ®Google Scholar
• Mavragani CP, Moutsopoulos HM. Sjogren syndrome. CMAJ 2014;186:E579-86
   PubMed Web of Science ®Google Scholar
• Tzioufas AG, Voulgarelis M. Update on Sjogren’s syndrome autoimmune epithelitis: from classification to increased neoplasias. Best Pract Res Clin Rheumatol 2007;21:989-1010
   PubMed Web of Science ®Google Scholar
• Malladi AS, Sack KE, Shiboski SC, et al. Primary Sjogren’s syndrome as a systemic disease: a study of participants enrolled in an international Sjogren’s syndrome registry. Arthritis Care Res (Hoboken) 2012;64:911-18
   PubMed Web of Science ®Google Scholar
• Ramos-Casals M, Brito-Zeron P, Solans R, et al. Systemic involvement in primary Sjogren’s syndrome evaluated by the EULAR-SS disease activity index: analysis of 921 Spanish patients (GEAS-SS Registry). Rheumatology (Oxford) 2014;53:321-31
   PubMed Web of Science ®Google Scholar
• Nocturne G, Mariette X. Sjogren Syndrome-associated lymphomas: an update on pathogenesis and management. Br J Haematol 2014. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Baimpa E, Dahabreh IJ, Voulgarelis M, et al. Hematologic manifestations and predictors of lymphoma development in primary Sjogren syndrome: clinical and pathophysiologic aspects. Medicine (Baltimore) 2009;88:284-93
   PubMed Web of Science ®Google Scholar
• Pollard RP, Pijpe J, Bootsma H, et al. Treatment of mucosa-associated lymphoid tissue lymphoma in Sjogren’s syndrome: a retrospective clinical study. J Rheumatol 2011;38:2198-208
   PubMed Web of Science ®Google Scholar
• Routsias JG, Goules JD, Charalampakis G, et al. Malignant lymphoma in primary Sjogren’s syndrome: an update on the pathogenesis and treatment. Semin Arthritis Rheum 2013;43:178-86
   PubMed Web of Science ®Google Scholar
• Baldini C, Pepe P, Quartuccio L, et al. Primary Sjogren’s syndrome as a multi-organ disease: impact of the serological profile on the clinical presentation of the disease in a large cohort of Italian patients. Rheumatology (Oxford) 2014;53:839-44
   PubMed Web of Science ®Google Scholar
• Vitali C, Bombardieri S, Jonsson R, et al. Classification criteria for Sjogren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002;61:554-8
   PubMed Web of Science ®Google Scholar
• Shiboski SC, Shiboski CH, Criswell L, et al. American College of Rheumatology classification criteria for Sjogren’s syndrome: a data-driven, expert consensus approach in the Sjogren’s International Collaborative Clinical Alliance cohort. Arthritis Care Res (Hoboken) 2012;64:475-87
   PubMed Web of Science ®Google Scholar
• Bootsma H, Spijkervet FK, Kroese FG, et al. Toward new classification criteria for Sjogren’s syndrome? Arthritis Rheum 2013;65:21-3
   PubMed Web of Science ®Google Scholar
• Seror R, Ravaud P, Bowman SJ, et al. Development of a consensus systemic disease activity index for primary Sjogren’s syndrome. Ann Rheum Dis 2010;69:1103-9
   PubMed Web of Science ®Google Scholar
• Meiners PM, Arends S, Brouwer E, et al. Responsiveness of disease activity indices ESSPRI and ESSDAI in patients with primary Sjogren’s syndrome treated with rituximab. Ann Rheum Dis 2012;71:1297-302
   PubMed Web of Science ®Google Scholar
• Moerman RV, Arends S, Meiners PM, et al. EULAR Sjogren’s Syndrome Disease Activity Index (ESSDAI) is sensitive to show efficacy of rituximab treatment in a randomised controlled trial. Ann Rheum Dis 2014;73:472-4
   PubMed Web of Science ®Google Scholar
• Seror R, Theander E, Brun JG, et al. Validation of EULAR primary Sjogren’s syndrome disease activity (ESSDAI) and patient indexes (ESSPRI). Ann Rheum Dis 2014. [Epub ahead of print]
   Web of Science ®Google Scholar
• Seror R, Bootsma H, Saraux A, et al. Defining disease activity states and clinically meaningful improvement in primary Sjogren’s syndrome with EULAR primary Sjogren’s syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI). Ann Rheum Dis 2014. [Epub ahead of print]
   Web of Science ®Google Scholar
• Lendrem D, Mitchell S, McMeekin P, et al. Health-related utility values of patients with primary Sjogren’s syndrome and its predictors. Ann Rheum Dis 2014;73:1362-8
   PubMed Web of Science ®Google Scholar
• Gottenberg JE, Seror R, Miceli-Richard C, et al. Serum levels of beta2-microglobulin and free light chains of immunoglobulins are associated with systemic disease activity in primary Sjogren’s syndrome. Data at enrollment in the prospective ASSESS cohort. PLoS One 2013;8:e59868
   PubMed Web of Science ®Google Scholar
• Hiepe F. Lupus nephritis: transatlantic management recommendations compared. Nat Rev Rheumatol 2012;8:697-8
   PubMed Web of Science ®Google Scholar
• Kaufman I, Schwartz D, Caspi D, et al. Sjogren’s syndrome - not just Sicca: renal involvement in Sjogren’s syndrome. Scand J Rheumatol 2008;37:213-18
   PubMed Web of Science ®Google Scholar
• Mori K, Iijima M, Koike H, et al. The wide spectrum of clinical manifestations in Sjogren’s syndrome-associated neuropathy. Brain 2005;128:2518-34
   PubMed Web of Science ®Google Scholar
• Parambil JG, Myers JL, Lindell RM, et al. Interstitial lung disease in primary Sjogren syndrome. Chest 2006;130:1489-95
   PubMed Web of Science ®Google Scholar
• Fox PC, Datiles M, Atkinson JC, et al. Prednisone and piroxicam for treatment of primary Sjogren’s syndrome. Clin Exp Rheumatol 1993;11:149-56
   PubMed Web of Science ®Google Scholar
• Marshak-Rothstein A. Toll-like receptors in systemic autoimmune disease. Nat Rev Immunol 2006;6:823-35
   PubMed Web of Science ®Google Scholar
• Kruize AA, Hene RJ, Kallenberg CG, et al. Hydroxychloroquine treatment for primary Sjogren’s syndrome: a two year double blind crossover trial. Ann Rheum Dis 1993;52:360-4
   PubMed Web of Science ®Google Scholar
• Gottenberg JE, Ravaud P, Puechal X, et al. Effects of hydroxychloroquine on symptomatic improvement in primary Sjogren syndrome: the JOQUER randomized clinical trial. JAMA 2014;312:249-58
   PubMed Web of Science ®Google Scholar
• Ramos-Casals M, Tzioufas AG, Stone JH, et al. Treatment of primary Sjogren syndrome: a systematic review. JAMA 2010;304:452-60
   PubMed Web of Science ®Google Scholar
• van Woerkom JM, Kruize AA, Geenen R, et al. Safety and efficacy of leflunomide in primary Sjogren’s syndrome: a phase II pilot study. Ann Rheum Dis 2007;66:1026-32
   PubMed Web of Science ®Google Scholar
• Mariette X, Ravaud P, Steinfeld S, et al. Inefficacy of infliximab in primary Sjogren’s syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjogren’s Syndrome (TRIPSS). Arthritis Rheum 2004;50:1270-6
   PubMed Web of Science ®Google Scholar
• Sankar V, Brennan MT, Kok MR, et al. Etanercept in Sjogren’s syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial. Arthritis Rheum 2004;50:2240-5
   PubMed Web of Science ®Google Scholar
• Carubbi F, Alunno A, Cipriani P, et al. Rituximab in primary Sjogren’s syndrome: a ten-year journey. Lupus 2014;23:1337-49
   PubMed Web of Science ®Google Scholar
• Meiners PM, Vissink A, Kallenberg CG, et al. Treatment of primary Sjogren’s syndrome with anti-CD20 therapy (rituximab). A feasible approach or just a starting point? Expert Opin Biol Ther 2011;11:1381-94
   PubMed Web of Science ®Google Scholar
• Dass S, Bowman SJ, Vital EM, et al. Reduction of fatigue in Sjogren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study. Ann Rheum Dis 2008;67:1541-4
   PubMed Web of Science ®Google Scholar
• Meijer JM, Meiners PM, Vissink A, et al. Effectiveness of rituximab treatment in primary Sjogren’s syndrome: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2010;62:960-8
   PubMed Web of Science ®Google Scholar
• Devauchelle-Pensec V, Mariette X, Jousse-Joulin S, et al. Treatment of primary Sjogren syndrome with rituximab: a randomized trial. Ann Intern Med 2014;160:233-42
   PubMed Web of Science ®Google Scholar
• Gottenberg JE, Cinquetti G, Larroche C, et al. Efficacy of rituximab in systemic manifestations of primary Sjogren’s syndrome: results in 78 patients of the AutoImmune and Rituximab registry. Ann Rheum Dis 2013;72:1026-31
   PubMed Web of Science ®Google Scholar
• Carubbi F, Cipriani P, Marrelli A, et al. Efficacy and safety of rituximab treatment in early primary Sjogren’s syndrome: a prospective, multi-center, follow-up study. Arthritis Res Ther 2013;15:R172
   PubMed Web of Science ®Google Scholar
• Cornec D, Devauchelle-Pensec V, Mariette X, et al. Development of the Sjögren’s Syndrome Responder Index (SSRI), a Data-Driven Composite Endpoint for Assessing Treatment Efficacy. Rheumatology 2015. [Epub ahead of print]
   Google Scholar
• Brown S, Navarro Coy N, Pitzalis C, et al. The TRACTISS protocol: a randomised double blind placebo controlled clinical trial of anti-B-cell therapy in patients with primary Sjogren’s Syndrome. BMC Musculoskelet Disord 2014;15:21
   PubMedGoogle Scholar
• Pers JO, Devauchelle V, Daridon C, et al. BAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of rituximab-treated patients with Sjogren’s syndrome. Arthritis Rheum 2007;56:1464-77
   PubMed Web of Science ®Google Scholar
• Sisto M, Lisi S, D’Amore M, et al. Rituximab-mediated Raf kinase inhibitor protein induction modulates NF-kappaB in Sjogren syndrome. Immunology 2014;143:42-51
   PubMed Web of Science ®Google Scholar
• Dorner T, Kaufmann J, Wegener WA, et al. Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Res Ther 2006;8:R74
   PubMed Web of Science ®Google Scholar
• Jacobi AM, Goldenberg DM, Hiepe F, et al. Differential effects of epratuzumab on peripheral blood B cells of patients with systemic lupus erythematosus versus normal controls. Ann Rheum Dis 2008;67:450-7
   PubMed Web of Science ®Google Scholar
• Daridon C, Blassfeld D, Reiter K, et al. Epratuzumab targeting of CD22 affects adhesion molecule expression and migration of B-cells in systemic lupus erythematosus. Arthritis Res Ther 2010;12:R204
   PubMed Web of Science ®Google Scholar
• Sieger N, Fleischer SJ, Mei HE, et al. CD22 ligation inhibits downstream B cell receptor signaling and Ca(2+) flux upon activation. Arthritis Rheum 2013;65:770-9
   PubMed Web of Science ®Google Scholar
• Steinfeld SD, Tant L, Burmester GR, et al. Epratuzumab (humanised anti-CD22 antibody) in primary Sjogren’s syndrome: an open-label phase I/II study. Arthritis Res Ther 2006;8:R129
   PubMed Web of Science ®Google Scholar
• Ota M, Duong BH, Torkamani A, et al. Regulation of the B cell receptor repertoire and self-reactivity by BAFF. J Immunol 2010;185:4128-36
   PubMed Web of Science ®Google Scholar
• Huang W, Moisini I, Bethunaickan R, et al. BAFF/APRIL inhibition decreases selection of naive but not antigen-induced autoreactive B cells in murine systemic lupus erythematosus. J Immunol 2011;187:6571-80
   PubMed Web of Science ®Google Scholar
• Quartuccio L, Salvin S, Fabris M, et al. BLyS upregulation in Sjogren’s syndrome associated with lymphoproliferative disorders, higher ESSDAI score and B-cell clonal expansion in the salivary glands. Rheumatology (Oxford) 2013;52:276-81
   PubMed Web of Science ®Google Scholar
• Furie R, Petri M, Zamani O, et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 2011;63:3918-30
   PubMed Web of Science ®Google Scholar
• Navarra SV, Guzman RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 2011;377:721-31
   PubMed Web of Science ®Google Scholar
• Manzi S, Sanchez-Guerrero J, Merrill JT, et al. Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. Ann Rheum Dis 2012;71:1833-8
   PubMed Web of Science ®Google Scholar
• Mariette X, Seror R, Quartuccio L, et al. Efficacy and safety of belimumab in primary Sjogren’s syndrome: results of the BELISS open-label phase II study. Ann Rheum Dis 2013. [Epub ahead of print]
   Google Scholar
• Adler S, Korner M, Forger F, et al. Evaluation of histologic, serologic, and clinical changes in response to abatacept treatment of primary Sjogren’s syndrome: a pilot study. Arthritis Care Res (Hoboken) 2013;65:1862-8
   PubMed Web of Science ®Google Scholar
• Meiners PM, Vissink A, Kroese FG, et al. Abatacept treatment reduces disease activity in early primary Sjogren’s syndrome (open-label proof of concept ASAP study). Ann Rheum Dis 2014;73(7):1393-6
   PubMed Web of Science ®Google Scholar
• Merrill JT, Wallace DJ, Petri M, et al. Safety profile and clinical activity of sifalimumab, a fully human anti-interferon alpha monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study. Ann Rheum Dis 2011;70:1905-13
   PubMed Web of Science ®Google Scholar
• Petri M, Wallace DJ, Spindler A, et al. Sifalimumab, a human anti-interferon-alpha monoclonal antibody, in systemic lupus erythematosus: a phase I randomized, controlled, dose-escalation study. Arthritis Rheum 2013;65:1011-21
   PubMed Web of Science ®Google Scholar
• de Weerd NA, Samarajiwa SA, Hertzog PJ. Type I interferon receptors: biochemistry and biological functions. J Biol Chem 2007;282:20053-7
   PubMed Web of Science ®Google Scholar
• Hall JC, Casciola-Rosen L, Berger AE, et al. Precise probes of type II interferon activity define the origin of interferon signatures in target tissues in rheumatic diseases. Proc Natl Acad Sci USA 2012;109:17609-14
   PubMed Web of Science ®Google Scholar
• Vincent FB, Saulep-Easton D, Figgett WA, et al. The BAFF/APRIL system: emerging functions beyond B cell biology and autoimmunity. Cytokine Growth Factor Rev 2013;24:203-15
   PubMed Web of Science ®Google Scholar
• O’Connor BP, Raman VS, Erickson LD, et al. BCMA is essential for the survival of long-lived bone marrow plasma cells. J Exp Med 2004;199:91-8
   PubMed Web of Science ®Google Scholar
• Genovese MC, Kinnman N, de La Bourdonnaye G, et al. Atacicept in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor antagonist therapy: results of a phase II, randomized, placebo-controlled, dose-finding trial. Arthritis Rheum 2011;63:1793-803
   PubMed Web of Science ®Google Scholar
• van Vollenhoven RF, Kinnman N, Vincent E, et al. Atacicept in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase II, randomized, placebo-controlled trial. Arthritis Rheum 2011;63:1782-92
   PubMed Web of Science ®Google Scholar
• Isenberg D, Gordon C, Licu D, et al. Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial). Ann Rheum Dis 2014. [Epub ahead of print]
   Web of Science ®Google Scholar
• Ma CS, Deenick EK, Batten M, et al. The origins, function, and regulation of T follicular helper cells. J Exp Med 2012;209:1241-53
   PubMed Web of Science ®Google Scholar
• Barr TA, Shen P, Brown S, et al. B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6-producing B cells. J Exp Med 2012;209:1001-10
   PubMed Web of Science ®Google Scholar
• Maier-Moore JS, Horton CG, Mathews SA, et al. Interleukin-6 Deficiency Corrects Nephritis, Lymphocyte Abnormalities, and Secondary Sjogren’s Syndrome Features in Lupus-Prone Sle1.Yaa Mice. Arthritis Rheumatol 2014;66:2521-31
   Web of Science ®Google Scholar
• Illei GG, Shirota Y, Yarboro CH, et al. Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum 2010;62:542-52
   PubMed Web of Science ®Google Scholar
• Shirota Y, Yarboro C, Fischer R, et al. Impact of anti-interleukin-6 receptor blockade on circulating T and B cell subsets in patients with systemic lupus erythematosus. Ann Rheum Dis 2013;72:118-28
   PubMed Web of Science ®Google Scholar
• Choi YS, Kageyama R, Eto D, et al. ICOS receptor instructs T follicular helper cell versus effector cell differentiation via induction of the transcriptional repressor Bcl6. Immunity 2011;34:932-46
   PubMed Web of Science ®Google Scholar
• Tangye SG, Ma CS, Brink R, et al. The good, the bad and the ugly - TFH cells in human health and disease. Nat Rev Immunol 2013;13:412-26
   PubMed Web of Science ®Google Scholar
• Szabo K, Papp G, Barath S, et al. Follicular helper T cells may play an important role in the severity of primary Sjogren’s syndrome. Clin Immunol 2013;147:95-104
   PubMed Web of Science ®Google Scholar
• Gong YZ, Nititham J, Taylor K, et al. Differentiation of follicular helper T cells by salivary gland epithelial cells in primary Sjogren’s syndrome. J Autoimmun 2014;51:57-66
   PubMed Web of Science ®Google Scholar
• Hu YL, Metz DP, Chung J, et al. B7RP-1 blockade ameliorates autoimmunity through regulation of follicular helper T cells. J Immunol 2009;182:1421-8
   PubMed Web of Science ®Google Scholar
• Weinstein JS, Bertino SA, Hernandez SG, et al. B cells in T follicular helper cell development and function: separable roles in delivery of ICOS ligand and antigen. J Immunol 2014;192:3166-79
   PubMed Web of Science ®Google Scholar
• Hua F, Comer GM, Stockert L, et al. Anti-IL21 receptor monoclonal antibody (ATR-107): safety, pharmacokinetics, and pharmacodynamic evaluation in healthy volunteers: a phase I, first-in-human study. J Clin Pharmacol 2014;54:14-22
   PubMed Web of Science ®Google Scholar
• Sundrud MS, Trivigno C. Identity crisis of Th17 cells: many forms, many functions, many questions. Semin Immunol 2013;25:263-72
   PubMed Web of Science ®Google Scholar
• Bettelli E, Oukka M, Kuchroo VK. T(H)-17 cells in the circle of immunity and autoimmunity. Nat Immunol 2007;8:345-50
   PubMed Web of Science ®Google Scholar
• Mease PJ, Genovese MC, Greenwald MW, et al. Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis. N Engl J Med 2014;370:2295-306
   PubMed Web of Science ®Google Scholar
• Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis–results of two phase 3 trials. N Engl J Med 2014;371:326-38
   PubMed Web of Science ®Google Scholar
• Gordon KB, Leonardi CL, Lebwohl M, et al. A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis. J Am Acad Dermatol 2014;71(6):1176-82
   PubMed Web of Science ®Google Scholar
• Genovese MC, Durez P, Richards HB, et al. Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study. Ann Rheum Dis 2013;72:863-9
   PubMed Web of Science ®Google Scholar
• Genovese MC, Greenwald M, Cho CS, et al. A phase II randomized study of subcutaneous ixekizumab, an anti-interleukin-17 monoclonal antibody, in rheumatoid arthritis patients who were naive to biologic agents or had an inadequate response to tumor necrosis factor inhibitors. Arthritis Rheumatol 2014;66:1693-704
   PubMed Web of Science ®Google Scholar
• Ciccia F, Guggino G, Rizzo A, et al. Potential involvement of IL-22 and IL-22-producing cells in the inflamed salivary glands of patients with Sjogren’s syndrome. Ann Rheum Dis 2012;71:295-301
   PubMed Web of Science ®Google Scholar
• Corsiero E, Bombardieri M, Manzo A, et al. Role of lymphoid chemokines in the development of functional ectopic lymphoid structures in rheumatic autoimmune diseases. Immunol Lett 2012;145:62-7
   PubMed Web of Science ®Google Scholar
• Fava RA, Kennedy SM, Wood SG, et al. Lymphotoxin-beta receptor blockade reduces CXCL13 in lacrimal glands and improves corneal integrity in the NOD model of Sjogren’s syndrome. Arthritis Res Ther 2011;13:R182
   PubMed Web of Science ®Google Scholar
• Kramer JM, Klimatcheva E, Rothstein TL. CXCL13 is elevated in Sjogren’s syndrome in mice and humans and is implicated in disease pathogenesis. J Leukoc Biol 2013;94:1079-89
   PubMed Web of Science ®Google Scholar
• Barone F, Bombardieri M, Manzo A, et al. Association of CXCL13 and CCL21 expression with the progressive organization of lymphoid-like structures in Sjogren’s syndrome. Arthritis Rheum 2005;52:1773-84
   PubMed Web of Science ®Google Scholar
• Gatumu MK, Skarstein K, Papandile A, et al. Blockade of lymphotoxin-beta receptor signaling reduces aspects of Sjogren’s syndrome in salivary glands of non-obese diabetic mice. Arthritis Res Ther 2009;11:R24
   PubMed Web of Science ®Google Scholar
• Bombardieri M, Barone F, Lucchesi D, et al. Inducible tertiary lymphoid structures, autoimmunity, and exocrine dysfunction in a novel model of salivary gland inflammation in C57BL/6 mice. J Immunol 2012;189:3767-76
   PubMed Web of Science ®Google Scholar
• O’Shea JJ, Plenge R. JAK and STAT signaling molecules in immunoregulation and immune-mediated disease. Immunity 2012;36:542-50
   PubMed Web of Science ®Google Scholar
• Vyas D, O’Dell KM, Bandy JL, et al. Tofacitinib: the First Janus Kinase (JAK) inhibitor for the treatment of rheumatoid arthritis. Ann Pharmacother 2013;47:1524-31
   PubMed Web of Science ®Google Scholar
• O’Shea JJ, Laurence A, McInnes IB. Back to the future: oral targeted therapy for RA and other autoimmune diseases. Nat Rev Rheumatol 2013;9:173-82
   PubMed Web of Science ®Google Scholar
• Hendriks RW, Yuvaraj S, Kil LP. Targeting Bruton’s tyrosine kinase in B cell malignancies. Nat Rev Cancer 2014;14:219-32
   PubMed Web of Science ®Google Scholar
• Boumpas DT, Furie R, Manzi S, et al. A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum 2003;48:719-27
   PubMed Web of Science ®Google Scholar
• Xie JH, Yamniuk AP, Borowski V, et al. Engineering of a novel anti-CD40L domain antibody for treatment of autoimmune diseases. J Immunol 2014;192:4083-92
   PubMed Web of Science ®Google Scholar
• Macauley MS, Pfrengle F, Rademacher C, et al. Antigenic liposomes displaying CD22 ligands induce antigen-specific B cell apoptosis. J Clin Invest 2013;123:3074-83
   PubMed Web of Science ®Google Scholar
• Seror R, Mariette X, Bowman S, et al. Accurate detection of changes in disease activity in primary Sjogren’s syndrome by the european league against rheumatism sjogren’s syndrome disease activity index. Arthritis Care Res (Hoboken) 2010;62:551-8
   PubMed Web of Science ®Google Scholar
• Das S, Vital EM, Horton S, et al. Abatacept or tocilizumab after rituximab in rheumatoid arthritis? An exploratory study suggests non-response to rituximab is associated with persistently high IL-6 and better clinical response to IL-6 blocking therapy. Ann Rheum Dis 2014;73:909-12
   PubMed Web of Science ®Google Scholar
• Gardette A, Ottaviani S, Tubach F, et al. High anti-CCP antibody titres predict good response to rituximab in patients with active rheumatoid arthritis. Joint Bone Spine 2014;81(5):416-20
   PubMed Web of Science ®Google Scholar
• Sellam J, Marion-Thore S, Dumont F, et al. Use of whole-blood transcriptomic profiling to highlight several pathophysiologic pathways associated with response to rituximab in patients with rheumatoid arthritis: data from a randomized, controlled, open-label trial. Arthritis Rheumatol 2014;66:2015-25
   PubMed Web of Science ®Google Scholar
• Raterman HG, Vosslamber S, de Ridder S, et al. The interferon type I signature towards prediction of non-response to rituximab in rheumatoid arthritis patients. Arthritis Res Ther 2012;14:R95
   PubMed Web of Science ®Google Scholar
• Kormelink TG, Tekstra J, Thurlings RM, et al. Decrease in immunoglobulin free light chains in patients with rheumatoid arthritis upon rituximab (anti-CD20) treatment correlates with decrease in disease activity. Ann Rheum Dis 2010;69:2137-44
   PubMed Web of Science ®Google Scholar
• Maria NI, Brkic Z, Waris M, et al. MxA as a clinically applicable biomarker for identifying systemic interferon type I in primary Sjogren’s syndrome. Ann Rheum Dis 2014;73:1052-9
   PubMed Web of Science ®Google Scholar
• Kroese FG, Bootsma H. Biomarkers: new biomarker for Sjogren’s syndrome–time to treat patients. Nat Rev Rheumatol 2013;9:570-2
   PubMed Web of Science ®Google Scholar
• Ambatipudi KS, Swatkoski S, Moresco JJ, et al. Quantitative proteomics of parotid saliva in primary Sjogren’s syndrome. Proteomics 2012;12:3113-20
   PubMed Web of Science ®Google Scholar
• Deutsch O, Krief G, Konttinen YT, et al. Identification of Sjogren’s syndrome oral fluid biomarker candidates following high-abundance protein depletion. Rheumatology (Oxford) 2014. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Hu S, Vissink A, Arellano M, et al. Identification of autoantibody biomarkers for primary Sjogren’s syndrome using protein microarrays. Proteomics 2011;11:1499-507
   PubMed Web of Science ®Google Scholar
• De Vita S, Quartuccio L, Salvin S, et al. Sequential therapy with belimumab followed by rituximab in Sjogren’s syndrome associated with B-cell lymphoproliferation and overexpression of BAFF: evidence for long-term efficacy. Clin Exp Rheumatol 2014;32:490-4
   PubMed Web of Science ®Google Scholar
• Berkowitz AL, Samuels MA. The neurology of Sjogren’s syndrome and the rheumatology of peripheral neuropathy and myelitis. Pract Neurol 2014;14:14-22
   PubMedGoogle Scholar
• Norheim KB, Harboe E, Goransson LG, et al. Interleukin-1 inhibition and fatigue in primary Sjogren’s syndrome–a double blind, randomised clinical trial. PLoS One 2012;7:e30123
   PubMed Web of Science ®Google Scholar